Medpace Holdings, Inc. (MEDP)

Market Cap	11.18B
Revenue (ttm)	2.03B
Net Income (ttm)	339.65M
Shares Out	30.93M
EPS (ttm)	10.64
PE Ratio	33.94
Forward PE	30.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	239,285
Open	357.25
Previous Close	354.65
Day's Range	354.99 - 367.23
52-Week Range	227.21 - 459.77
Beta	1.36
Analysts	Strong Buy
Price Target	426.50 (+18.05%)
Earnings Date	Oct 21, 2024

About MEDP

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 5,900
• Stock Exchange: NASDAQ
• Ticker Symbol: MEDP
• Website: https://www.medpace.com

Financial Performance

In 2023, Medpace Holdings's revenue was $1.89 billion, an increase of 29.17% compared to the previous year's $1.46 billion. Earnings were $282.62 million, an increase of 15.26%.

Analyst Forecast

According to 9 analysts, the average rating for MEDP stock is "Strong Buy." The 12-month stock price forecast is $426.5, which is an increase of 18.05% from the latest price.

Price Target

$426.5

(18.05% upside)

Analyst Consensus: Strong Buy